Resistance Data Across 9 Clinical Trials
Explore the BIKTARVY resistance overviewLong-term Treatment-Naïve Efficacy Data
Discover BIKTARVY 5-year efficacy data5-Year Long-term Safety and Tolerability Profile
Explore BIKTARVY safety dataNew Updates for These Special Populations Within the Prescribing Information
Study 4030: Virologically Suppressed Adults, Including Those With Known or Suspected Preexisting M184V/I Resistance Mutation
Explore the dataStudy 5310: Virologically Suppressed Adult Women Who Are Pregnant
View the Prescribing Information to learn more about this population#1 PRESCRIBED REGIMEN FOR PEOPLE STARTING AND SWITCHING HIV-1 TREATMENT
Fueled by the power of bictegravir1
SOURCE: IQVIA LAAD, April 2020 through April 2023*
Hear from key opinion leaders, Joel E. Gallant, MD, MPH, and Calvin J. Cohen, MD, MSc, as they discuss the events that shaped the way providers approach HIV treatment. Drs. Gallant and Cohen are both employees of Gilead.
See Dr. Joel Gallant and Dr. Calvin Cohen discuss more HIV topics:
*This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period of April 2020 through April 2023. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.
Reference: 1. Data on file. Gilead Sciences, Inc.